Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on gene therapy for hemoglobin disorders.

Derek A Persons1

  • 1St Jude Children's Research Hospital, 332 North Lauderdale Drive, Memphis, TN 38105, USA. derek.persons@stjude.org

Current Opinion in Molecular Therapeutics
|November 7, 2003
PubMed
Summary

Gene therapy offers new hope for hemoglobin disorders like beta-thalassemia and sickle cell disease. Recent advances in lentiviral vectors and stem cell modification show promise for effective treatments, improving patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia.

Molecular therapy : the journal of the American Society of Gene Therapy·2017
Same author

Data in support of transcriptional regulation and function of Fas-antisense long noncoding RNA during human erythropoiesis.

Data in brief·2016
Same author

Fas-antisense long noncoding RNA is differentially expressed during maturation of human erythrocytes and confers resistance to Fas-mediated cell death.

Blood cells, molecules & diseases·2016
Same author

Long noncoding RNA Saf and splicing factor 45 increase soluble Fas and resistance to apoptosis.

Oncotarget·2016
Same author

Increased Engraftment of Human Short Term Repopulating Hematopoietic Cells in NOD/SCID/IL2rγnull Mice by Lentiviral Expression of NUP98-HOXA10HD.

PloS one·2016
Same author

Amelioration of murine sickle cell disease by nonablative conditioning and γ-globin gene-corrected bone marrow cells.

Molecular therapy. Methods & clinical development·2015

Area of Science:

  • * Hematology
  • * Gene Therapy
  • * Molecular Biology

Background:

  • * Hemoglobin disorders, including beta-thalassemia and sickle cell disease, are the most common monogenic diseases globally.
  • * Current treatments like palliative care and stem cell transplantation have limitations, leading to persistent morbidity and mortality.
  • * Gene therapy presents a promising alternative for treating these inherited blood disorders.

Purpose of the Study:

  • * To review recent advancements in gene therapy for hemoglobin disorders.
  • * To highlight the potential of lentiviral vectors for therapeutic gene delivery.
  • * To discuss the progress in stem cell manipulation for in vivo correction.

Main Methods:

  • * Utilization of lentiviral vectors for efficient gene transfer of complex globin gene cassettes.
  • * Development of methods for selecting and expanding genetically modified stem cells in vivo.
  • * Review of safety considerations associated with retroviral gene transfer.

Main Results:

  • * Successful therapeutic correction of murine models for both beta-thalassemia and sickle cell disease.
  • * Demonstrated high-level expression of therapeutic globin genes using lentiviral vectors.
  • * Significant progress in in vivo stem cell expansion and genetic modification.

Conclusions:

  • * Gene therapy, particularly using lentiviral vectors, has shown significant therapeutic potential for hemoglobin disorders.
  • * Advances in stem cell technology enhance the feasibility of in vivo gene correction.
  • * Continued research and safety evaluations are crucial for the clinical translation of gene therapy for these prevalent genetic diseases.

Related Experiment Videos